Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | BCHE | P06276 | 2/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | AR | P10275 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11714868 | 0.89 | MEN1 (0.67) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL791985 | 0.89 | MAOB (0.69) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL9703808 | 0.88 | EGFR (0.59) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL8737849 | 0.86 | AR (0.65) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| Benzylphenylether SCHEMBL28164613 | 0.85 | MAOB (0.75) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL19382100 | 0.85 | AR (0.59) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL2113895 | 0.84 | CYP1A2 (0.57) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL8845456 | 0.84 | LTA4H (0.63) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL553770 | 0.83 | APP (0.69) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL1465278 | 0.83 | KMT2A (0.70) | NPC1RAB9ASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624161-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624161-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9427418-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9051267-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051267-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20150087712-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2015-03-26 | — | — | US | disclosed |
| EP-2455362-A1 | Nuclear receptor binding agents | GTX, Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| US-8158828-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| CN-102413692-A | Estrogen receptor ligands and methods of use thereof | GTX INC | 2012-04-11 | — | — | CN | disclosed |
| US-20120077845-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2012-03-29 | — | — | US | disclosed |
| WO-2011106317-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
| US-20100267773-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100267773-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| WO-2010096801-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20090062341-A1 | Nuclear receptor binding agents | GTX, INC | 2009-03-05 | — | — | US | disclosed |
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077845-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GNRHR, LHCGR, SHBG | NPC1 1575/4885RAB9A 4458/4885SMN1; SMN2 4770/4885 |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | ESRRB, ESRRA, ESR2 | NPC1 886/4885RAB9A 3825/4885SMN1; SMN2 4468/4885 |
| US-20070265296-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | NPC1 1103/4885RAB9A 3636/4885SMN1; SMN2 2521/4885 |
| US-20090062341-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | NPC1 1103/4885RAB9A 3636/4885SMN1; SMN2 2521/4885 |
| US-20100267773-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | SHBG, GNRHR, FSHR | NPC1 2417/4885RAB9A 4045/4885SMN1; SMN2 4863/4885 |
| US-20150087712-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | SHBG, AR, NR5A1 | NPC1 1645/4885RAB9A 3876/4885SMN1; SMN2 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.